PHGPhilips is navigating a complex market with ongoing restructuring, showing mixed fundamental performance. Its position in health technology offers long-term potential, but near-term headwinds and mixed technical signals warrant a cautious approach.
Philips operates in the essential healthcare and personal health sectors, which benefit from long-term demographic trends and increasing health consciousness. However, the company faces competitive pressures and execution risks within these themes.
Philips exhibits a mixed financial profile. While revenue has shown some stability, profitability remains a concern, with recent net losses and elevated P/E ratios. The balance sheet is moderately leveraged with manageable debt coverage.
The stock is showing bullish momentum in the short to medium term, trading above key moving averages. However, some oscillators are entering overbought territory, suggesting potential for consolidation or a minor pullback.
| Factor | Score |
|---|---|
| Healthcare Technology Advancement | 85 |
| Aging Global Population | 80 |
| Digital Health & Connectivity | 75 |
| Personal Health & Wellness | 70 |
| Regulatory & Recall Impacts | 40 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 15 |
| Growth | 45 |
| Balance Sheet Health | 60 |
| Cash Flow | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 70 |
Strong Cash Position
The company has substantial cash and cash equivalents of $2,401,000,000 (as of 2024Q4), providing significant liquidity and financial flexibility.
Positive Free Cash Flow
Positive free cash flow of $893,000,000 in the trailing twelve months (2024Q4) indicates the company generates enough cash to cover its capital expenditures and operational needs.
Overall Net Loss
The company reported a net loss of $702,000,000 for the full year 2024 and a net loss of $335,000,000 in the most recent quarter (2024Q4), indicating ongoing profitability challenges.
High P/E Ratio (TTM)
The trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio is -306.5 due to net losses, making traditional P/E valuation metrics uninformative and suggesting a potentially overvalued stock if profitability does not improve.
May 2025
13
Ex-Dividend Date
June 2025
6
Next Dividend Date
July 2025
29
Next Earnings Date
H: $0.29
A: $0.29
L: $0.29
H: 4.39B
A: 4.34B
L: 4.31B
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. It provides diagnostic imaging solutions, includes magnetic resonance imaging; X-ray systems; and computed tomography (CT) systems and software comprising detector-based spectral CT solutions; ultrasound imaging solutions focused on diagnosis, treatment planning and guidance for cardiac, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional X-ray systems and software solutions; and interventional image devices and software to aid in the diagnosis, navigation, treatment, and confirmation in minimally invasive interventional coronary, peripheral vascular, and hearth rhythm management procedures. The company also offers acute patient management solutions; emergency care solutions; patient care management in ambulatory and home care; sleep and respiratory care solutions; and vendor-agnostic software solutions. In addition, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental and women's health solutions; and grooming and beauty products and solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
32.43 USD
The 39 analysts offering 1 year price forecasts for PHG have a max estimate of 41.00 and a min estimate of 26.00.